Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in Relapsed/Refractory Squamous NSCLC
NCT05275673Phase 2Terminated
- Sponsor
- Faeth Therapeutics
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in squamous cell carcinoma of the lung (SCCL), sponsored by Faeth Therapeutics. Started Jul 2022; status: terminated.
02
Drugs
sapanisertib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05275673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275673.